BIO-Key International Inc (BKYI) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BIO-Key International Inc stock $0.59, price $2.38, that is 75.4% below the price, quality 33 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $1.65 – $651.60 · fair‑value band $0.3825 – $0.7310 · the $2.38 price screens above the $0.5865 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow BIO-Key International in your weekly email
Every Wednesday you see whether BIO-Key International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education sectors in the United States and internationally.
Show moreShow less
It offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premise SaaS application, services, and cloud host, as well as windows device authentication through IAM platform.
The company's solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative.
In addition, it provides BIO-key VST and WEB-key products; and civil and large-scale ID infrastructure solutions that develop finger-based biometric technology.
Further, the company offers finger scanners for enterprise and consumer markets under SideSwipe, PIV Pro, EcoID II, and SidePass brand names; and fingerprint readers.
Additionally, it provides identity and access management, user multi-factor authentication, and privilege entitlement and access control solutions. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002.
BIO-key International, Inc. was founded in 1993 and is headquartered in Holmdel, New Jersey.
Stock analysis
BIO-Key International Inc (BKYI) currently trades at $2.38, while our model-based Fair Value estimate is $0.5865, 75% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.3825 (bear) to $0.7310 (bull), the price of $2.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Industrials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
BIO-Key International Inc reported revenue of $6.1M in FY2025 versus $5.1M in FY2021, a compound +4.5%/yr. Reported net income was −$4.6M in FY2025.
Key figures
Market cap $6.4M Micro · P/S ratio 0.95 · EPS (TTM) $−8.02 · Net margin −90.1% · Return on equity −108% · Return on assets (EBIT) −79.3% (5-year average) · Operating margin −27.6% · Revenue (TTM) $6.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 77% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 1% fair-value upside, at −75%, BKYI screens richer than that median.
Fair Value models
Bear$0.3825Fair Value $0.5865Bull$0.7310
Price $2.38 · Downside -75.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.4500$0.6900$0.860054
All 1 models by family
Asset-Based
NCAV (Graham)$0.4500$0.6900$0.860054
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Start year 2020 (pandemic). Over 10 years: +1.5% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−183.4% (2020) → −69.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare BIO-Key International Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Security & Protection Services · 105 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BIO-Key International Inc Fair Value". https://www.fairvalue-calculator.com/stock/BKYI
Frequently asked questions
Is BIO-Key International Inc (BKYI) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.5865 versus a price of $2.38, about 75% lower (overvalued).
What is the fair value of BKYI?
Our model-based fair value for BIO-Key International Inc is $0.5865 (as of Nov 7, 2026), built from audited fundamentals. The current price: $2.38.
What is the quality score of BKYI?
BIO-Key International Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BIO-Key International Inc (BKYI)?
Our model-based price target is the fair value of $0.5865 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $0.3825, optimistic scenario $0.7310. It is a calculation from audited fundamentals, not an analyst target.
What is the BIO-Key International Inc stock forecast for 2026?
Our models put fair value at $0.5865, about 75% lower versus a price of $2.38 (overvalued). Cautious scenario $0.3825, optimistic scenario $0.7310. The calculation is refreshed regularly with new filings.
What is the revenue of BIO-Key International Inc (BKYI)?
BIO-Key International Inc reported trailing-twelve-month revenue of about $6.7M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of BIO-Key International Inc (BKYI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BIO-Key International Inc it is $0.5865 per share (as of Nov 7, 2026), against a price of $2.38. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is BIO-Key International Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, BKYI trades above its calculated fair value: price $2.38, fair value $0.5865, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BKYI?
No. The price is what the market pays today ($2.38); the fair value is what the company's own numbers justify ($0.5865). For BIO-Key International Inc the two are $1.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is BIO-Key International Inc worth?
The market values BIO-Key International Inc at about $6.4M (market capitalisation, as of Nov 7, 2026). Per share that is $2.38; our models calculate a fair value of $0.5865 per share.
What do the bullish and bearish scenarios say about BKYI?
Our models span a range for BIO-Key International Inc: cautious scenario $0.3825, base $0.5865, optimistic $0.7310 per share (as of Nov 7, 2026, price $2.38). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BIO-Key International Inc (BKYI)?
Balance-sheet figures for BIO-Key International Inc (as of Nov 7, 2026): return on equity −107.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is BKYI from its 52-week high?
BIO-Key International Inc trades at $2.38, about 77% below its 52-week high of $10.30 and 44% above the low of $1.65 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5865 is for.
Which stocks are comparable to BIO-Key International Inc?
From the same area (Industrials) we also value Allegion plc, ADT Inc, Zhejiang Dahua Technology Co, MSA Safety Incorporated, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BIO-Key International Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $2.38, calculated fair value $0.5865 (−75%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BKYI calculated?
We run BIO-Key International Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.5865 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BIO-Key International Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BIO-Key International Inc (BKYI)?
The closing price on Nov 6, 2026 was $2.38. Our model-based fair value is $0.5865, about 75% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BIO-Key International Inc right now?
The price sits above even our optimistic bull case ($0.7310). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3825 to $0.7310) leaves room in how you read the outcome.
Key figures of BIO-Key International Inc
How large is the market capitalisation of BIO-Key International Inc (BKYI)?
The market capitalisation of BIO-Key International Inc is $6.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BIO-Key International Inc (BKYI)?
The price-to-sales ratio of BIO-Key International Inc is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BIO-Key International Inc (BKYI)?
Earnings per share at BIO-Key International Inc are $−8.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BIO-Key International Inc (BKYI)?
The net margin of BIO-Key International Inc is −90.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BIO-Key International Inc (BKYI)?
The return on equity (ROE) of BIO-Key International Inc is −108% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BIO-Key International Inc (BKYI)?
On an EBIT basis the return on assets of BIO-Key International Inc is −79.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BIO-Key International Inc (BKYI)?
The operating margin of BIO-Key International Inc is −27.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BIO-Key International Inc (BKYI)?
Revenue at BIO-Key International Inc is growing +13.1% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BIO-Key International Inc (BKYI) generate?
The free cash flow of BIO-Key International Inc is −$4.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BIO-Key International Inc (BKYI) hold?
BIO-Key International Inc holds more cash than debt, $2.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BIO-Key International Inc in the live analysis
One click puts BIO-Key International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026
